Understanding that weight loss may take time or require additional treatments can help manage expectations and avoid frustration
Beyond diabetes and obesity, research is now underway to explore the potential of GLP-1 agonists for other conditions like kidney disease, heart failure, Alzheimers, Parkinsons, sleep apnea and drug addiction, she said
These numbers are lower than the clinical trials because real-world patients are less adherent, have more comorbidities, and may not reach the maximum dose
If you find that appetite suppression alone does not change your eating behaviors, that is equally valuable information that can guide future treatment decisions
Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA adverse event reporting system